Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

[IgE-κ type multiple myeloma achieving complete response with novel agents].

Author information

Affiliations

  • 1. Department of Hematology, Japanese Red Cross Medical Center.
      Authors
    • Takei T 1
    • Ishida T 1
    • Ikeda M 1
    • Shingaki S 1
    • Miyazaki K 1
    • Yoshiki Y 1
    • Abe Y 1
    • Okazuka K 1
    • Iki S 1
    • Tsukada N 1
    • Suzuki K 1
    (11 authors)

ORCIDs linked to this article

[Rinsho Ketsueki] The Japanese Journal of Clinical Hematology, 01 Jan 2017, 58(11):2232-2237Language:jpn
https://doi.org/10.11406/rinketsu.58.2232 PMID: 29212974 

Review

Abstract 

IgE multiple myeloma (MM) is a rare subtype of MM characterized by an aggressive and poor prognosis. Although novel agents have improved the prognosis of MM, there are few case reports of IgE MM treated with these agents. A 53-year-old male patient presented with pain in the right rib and was diagnosed with IgE-κ MM. He was treated with multidrug chemotherapy, including bortezomib and lenalidomide, and underwent autologous stem-cell transplantation (ASCT). Finally, he achieved a complete response after the initiation of pomalidomide. In previous reports, majority of patients with refractory IgE MM treated with novel agents had a poor prognosis. In contrast, patients who were treated with novel agents from the beginning and underwent ASCT had a long-term survival. Overall, the use of novel agents as the first-line therapy is expected to improve IgE MM prognosis.

Full text links 

Read article at publisher's site: https://doi.org/10.11406/rinketsu.58.2232

Citations & impact 

Impact metrics

1
Citation
Jump to Citations

Article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.